Investor Presentaiton

Marinosolv explained based on Budesolv MarinosolvⓇ allows to provide Budesonide in solution offering a competitive edge marino med Suspension Rhinocort Aqua Budesonide nasal spray 64μg per dose/spray Rhinocort Aqua Rhinocort Aqua 64 Marinosolv Proven solubility Increasing market Patent protected Properties Solubility increase versus water shown for variety of compounds Higher specificity of compounds leads to lower solubility → increasing number of APIs that could benefit from Marinosolv Patent in nationalisation phase USPS Solution MarinosolvⓇ enabled Budesonide nasal spray 10μg per dose/spray Increased bioavailability Faster onset of action Higher local, lower systemic availability Dose reduction Lower possible side effects Lower production costs Aseptic filtering Preservative free formulation Lower production costs a technology platform with the potential to facilitate delivery of any compound with Marinosolv solubility issues 11

View entire presentation